Matthew W Kemp1, Yuichiro Miura1, Matthew S Payne1, Rory Watts1, Smruthi Megharaj1, Alan H Jobe2, Suhas G Kallapur2, Masatoshi Saito3, O Brad Spiller4, Jeffrey A Keelan1, John P Newnham1. 1. School of Women's and Infants' Health, University of Western Australia, Perth, WA, Australia. 2. School of Women's and Infants' Health, University of Western Australia, Perth, WA, Australia; Division of Pulmonary Biology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH. 3. School of Women's and Infants' Health, University of Western Australia, Perth, WA, Australia; Division of Perinatal Medicine Centre for Perinatal and Neonatal Care, Tohoku University Hospital, Sendai, Miyagi Prefecture, Japan. 4. Department of Child Health, School of Medicine, Cardiff University, Cardiff, UK.
Abstract
OBJECTIVE: Ureaplasma spp are the most commonly isolated microorganisms in association with preterm birth. Maternal erythromycin administration is a standard treatment for preterm prelabor rupture of membranes. There is little evidence of its effectiveness in eradicating Ureaplasma spp from the intrauterine cavity and fetus. We used a sheep model of intrauterine Ureaplasma spp infection to investigate the efficacy of repeated maternal intramuscular and intraamniotic erythromycin treatment to eradicate such an infection. STUDY DESIGN: Thirty ewes with singleton pregnancies received an intraamniotic injection of 10(7) color change units of erythromycin-sensitive Ureaplasma parvum serovar 3 at 55 days' gestation. At 116 days' gestation, 28 ewes with viable fetuses were randomized to receive (1) intraamniotic and maternal intramuscular saline solution treatment (n = 8), (2) single intraamniotic and repeated maternal intramuscular erythromycin treatment (n = 10), or (3) single maternal intramuscular and repeated intraamniotic erythromycin treatment (n = 10). Fetuses were surgically delivered at 125 days' gestation. Treatment efficacy was assessed by culture, quantitative polymerase chain reaction, and histopathologic evaluation. RESULTS: Animals treated with intraamniotic erythromycin had significantly less viable U parvum serovar 3 in the amniotic fluid at delivery. However, neither combination of maternal intramuscular and intraamniotic erythromycin treatment successfully cleared U parvum serovar 3 from the amniotic fluid or fetal tissues. Three de novo erythromycin-resistant U parvum isolates were identified in erythromycin-treated animals. CONCLUSION: Erythromycin treatment, given both to the ewe and into the amniotic cavity, fails to eradicate intrauterine and fetal U parvum serovar 3 infection and may lead to development of erythromycin resistant U parvum.
OBJECTIVE:Ureaplasma spp are the most commonly isolated microorganisms in association with preterm birth. Maternal erythromycin administration is a standard treatment for preterm prelabor rupture of membranes. There is little evidence of its effectiveness in eradicating Ureaplasma spp from the intrauterine cavity and fetus. We used a sheep model of intrauterine Ureaplasma spp infection to investigate the efficacy of repeated maternal intramuscular and intraamniotic erythromycin treatment to eradicate such an infection. STUDY DESIGN: Thirty ewes with singleton pregnancies received an intraamniotic injection of 10(7) color change units of erythromycin-sensitive Ureaplasma parvum serovar 3 at 55 days' gestation. At 116 days' gestation, 28 ewes with viable fetuses were randomized to receive (1) intraamniotic and maternal intramuscular saline solution treatment (n = 8), (2) single intraamniotic and repeated maternal intramuscular erythromycin treatment (n = 10), or (3) single maternal intramuscular and repeated intraamniotic erythromycin treatment (n = 10). Fetuses were surgically delivered at 125 days' gestation. Treatment efficacy was assessed by culture, quantitative polymerase chain reaction, and histopathologic evaluation. RESULTS: Animals treated with intraamniotic erythromycin had significantly less viable U parvum serovar 3 in the amniotic fluid at delivery. However, neither combination of maternal intramuscular and intraamniotic erythromycin treatment successfully cleared U parvum serovar 3 from the amniotic fluid or fetal tissues. Three de novo erythromycin-resistant U parvum isolates were identified in erythromycin-treated animals. CONCLUSION:Erythromycin treatment, given both to the ewe and into the amniotic cavity, fails to eradicate intrauterine and fetal U parvum serovar 3infection and may lead to development of erythromycin resistant U parvum.
Authors: Matthew Josiah Allen-Daniels; Myrna G Serrano; Lindsey P Pflugner; Jennifer M Fettweis; Melissa A Prestosa; Vishal N Koparde; J Paul Brooks; Jerome F Strauss; Roberto Romero; Tinnakorn Chaiworapongsa; David A Eschenbach; Gregory A Buck; Kimberly K Jefferson Journal: Am J Obstet Gynecol Date: 2015-01-28 Impact factor: 8.661
Authors: Stacey J Ellery; Meredith Kelleher; Peta Grigsby; Irina Burd; Jan B Derks; Jon Hirst; Suzanne L Miller; Larry S Sherman; Mary Tolcos; David W Walker Journal: J Physiol Date: 2018-07-21 Impact factor: 5.182
Authors: Yuichiro Miura; Matthew S Payne; Jeffrey A Keelan; Andres Noe; Sean Carter; Rory Watts; Owen B Spiller; Alan H Jobe; Suhas G Kallapur; Masatoshi Saito; Sarah J Stock; John P Newnham; Matthew W Kemp Journal: Antimicrob Agents Chemother Date: 2014-06-30 Impact factor: 5.191
Authors: John P Newnham; Jan E Dickinson; Roger J Hart; Craig E Pennell; Catherine A Arrese; Jeffrey A Keelan Journal: Front Immunol Date: 2014-11-19 Impact factor: 7.561
Authors: Katherine M Nelson; N'Dea Irvin-Choy; Matthew K Hoffman; Jason P Gleghorn; Emily S Day Journal: Adv Drug Deliv Rev Date: 2020-09-28 Impact factor: 15.470